JPMORGAN CHASE & CO - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$40,924,158
-22.6%
601,207
-7.2%
0.01%
-16.7%
Q2 2023$52,871,915
+27.0%
647,702
+15.5%
0.01%
+20.0%
Q1 2023$41,621,000
+96461.7%
560,985
+7.9%
0.01%
-16.7%
Q4 2022$43,103
-99.9%
520,083
+259.5%
0.01%0.0%
Q3 2022$41,084,000
-21.7%
144,667
-4.4%
0.01%
-14.3%
Q2 2022$52,457,000
-20.6%
151,328
-0.8%
0.01%
-12.5%
Q1 2022$66,058,000
-20.7%
152,549
-5.3%
0.01%
-20.0%
Q4 2021$83,340,000
-20.8%
161,091
-25.8%
0.01%
-23.1%
Q3 2021$105,240,000
+7.6%
217,184
-0.1%
0.01%
+8.3%
Q2 2021$97,851,000
+22.6%
217,322
+4.0%
0.01%
+9.1%
Q1 2021$79,823,000
+59.6%
208,998
+32.7%
0.01%
+57.1%
Q4 2020$50,008,000
+79.7%
157,477
+39.6%
0.01%
+40.0%
Q3 2020$27,828,000
+7.9%
112,777
+15.5%
0.01%0.0%
Q2 2020$25,782,000
+85.1%
97,633
+32.9%
0.01%
+66.7%
Q1 2020$13,930,000
-6.5%
73,462
+8.2%
0.00%0.0%
Q4 2019$14,904,000
+7.9%
67,900
-3.8%
0.00%0.0%
Q3 2019$13,818,000
+59.3%
70,614
+68.0%
0.00%
+50.0%
Q2 2019$8,676,000
-2.6%
42,036
-6.3%
0.00%0.0%
Q1 2019$8,909,000
+43.0%
44,864
+4.2%
0.00%
+100.0%
Q4 2018$6,230,000
-60.3%
43,043
-44.0%
0.00%
-66.7%
Q3 2018$15,686,000
+55.1%
76,856
+12.4%
0.00%
+50.0%
Q2 2018$10,116,000
-2.3%
68,376
-0.2%
0.00%0.0%
Q1 2018$10,353,000
+85.4%
68,545
+59.1%
0.00%
+100.0%
Q4 2017$5,583,000
+3672.3%
43,094
+3412.1%
0.00%
Q3 2017$148,000
-79.1%
1,227
-79.7%
0.00%
Q2 2017$709,000
+786.2%
6,034
+665.7%
0.00%
Q1 2017$80,000
-88.3%
788
-88.1%
0.00%
Q4 2016$681,000
+229.0%
6,619
+251.7%
0.00%
Q3 2016$207,000
-51.2%
1,882
-50.0%
0.00%
Q2 2016$424,000
+41.3%
3,765
+19.0%
0.00%
Q1 2016$300,000
+87.5%
3,164
+78.6%
0.00%
Q4 2015$160,000
-42.2%
1,772
-40.9%
0.00%
Q3 2015$277,000
-83.6%
2,998
-82.2%
0.00%
Q1 2015$1,686,000
-62.8%
16,806
-65.8%
0.00%
-100.0%
Q4 2014$4,537,00049,0990.00%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders